
Full text loading...
We use cookies to track usage and preferences.I Understand
Metformin is a key treatment for type 2 diabetes, often linked to oxidative stress and genetic factors like GSTM1 and GSTT1 variations.
We studied 150 subjects, examining how their deletion polymorphisms in these genes correlate with Met treatment response. Those with GSTM1/T1 deletions (-/-) had a higher T2DM risk (2.71-fold, P=0.005).
Met responders with GSTM1(16bp) deletions had lower glucose levels compared to non-responders (P<0.0001), and similar trends were observed with GSTT1(54bp) deletions. Responders with both deletions also managed lipids better (P=0.0256; P=0.0151). Non-responders with GSTM1/T1 null genotypes had better HDL management (P=0.007).
These findings suggested that GSTM1 deletion could predict T2DM susceptibility and Met response.
Article metrics loading...
Full text loading...
References
Data & Media loading...